Pfizer Inc.
Vectors for expression of prostate-associated antigens
Last updated:
Abstract:
The present disclosure provides (a) vectors comprising a multi-antigen construct encoding two, three, or more immunogenic PAA polypeptides; (b) compositions comprising the vectors, (c) methods relating to uses of the vectors and compositions for eliciting an immune response or for treating prostate cancers.
Status:
Grant
Type:
Utility
Filling date:
23 Aug 2018
Issue date:
16 Nov 2021